EuroMedix Screening for
Cardio-Metabolic Disease
in the Middle East since 2008
Metabolic Syndrome (MS) is a combination of medical disorders that, taken together, increase the risk of cardiovascular disease and diabetes. It affects about one in four people in the Middle East, and prevalence increases with age. The recorded high frequency of MS and its key cardiovascular risk factors (15-60%) among the Middle East population mandates the need for prevention programmes to combat obesity, diabetes, hypertension, dyslipidemia, smoking and related comorbidities. Early prevention and control is of utmost importance.
EuroMedix provides health-screening tools and implements concepts related to:
A further dimension of Cardiometabolic Health & Advanced Risk Management (CHARM) concerns new technologies that measure vascular age, arterial stiffness, AGEs (Advanced Glycation End-products) ... Diverse EuroMedix technologies have been used to assess cardio-metabolic health in the Middle-East:
|
|